IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New injection aims to control kidney disease in IgA nephropathy patients
Disease control Not yet recruitingThis study tests a new drug called CM313, given as an injection under the skin, for people with a kidney disease called IgA nephropathy. The goal is to see if it is safe and helps control the disease. About 106 adults with confirmed IgA nephropathy and moderate kidney function wi…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated May 17, 2026 03:53 UTC
-
New hope for kidney disease: drug targets protein leak
Disease control Not yet recruitingThis study tests a new drug called NM8074 in 10 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug safely reduces protein in the urine, a sign of kidney damage, after 99 days of treatment. Participants must have had a kid…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: NovelMed Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for kidney patients: JADE101 trial launches
Disease control Not yet recruitingThis study tests a new drug, JADE101, in 30 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants must be on stable standard care before joining.
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Jade Biosciences, Inc. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New hope for kids with kidney disease: drug trial targets protein leak
Disease control Not yet recruitingThis study tests an oral drug called atrasentan in 28 children aged 2 to 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The main goal is to see if the drug reduces protein in the urine, a sign of kidney damage, over 36 weeks. Participants will take the…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 05, 2026 11:55 UTC
-
New study tracks Real-Life use of kidney drugs in IgA nephropathy
Knowledge-focused Not yet recruitingThis study will follow about 80 adults with IgA nephropathy (a kidney disease) who are starting treatment with iptacopan or atrasentan. Researchers want to see how these drugs work in everyday medical practice, not in a controlled experiment. Each person will be observed for 24 m…
Matched conditions: IGA NEPHROPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 08, 2026 12:04 UTC